Ghinwa Dumyati

Ghinwa Dumyati

Auto-generated profile, based on publicly available information

Ghinwa Dumyati

New York Emerging Infections Program, University of Rochester Medical Center , Rochester, New York

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SMShelley S Magill
Shelley S Magill
EOErin O’leary
Erin O’leary
SRSusan M Ray
Susan M Ray
MKMarion A Kainer
Marion A Kainer
CEChristopher Evans
Christopher Evans
VRVicky P Reed
Vicky P Reed
In the 2011 US hospital prevalence survey of healthcare-associated infections and antimicrobial use 50% of patients received antimicrobial medications on the survey date or day before. More hospitals have since established antimicrobial stewardship programs. We repeated the survey in 2015 to determine antimicrobial use prevalence and describe changes since 2011. The Centers for Disease Control and Prevention’s Emerging Infections Program sites in 10 states each recruited ≤25 general and women’s and children’s hospitals. Hospitals selected a survey date from May–September 2015. Medical records for a random patient sample on the survey date were reviewed to collect data on antimicrobial medications administered on the survey date or day before. Percentages of patients on antimicrobial medications were compared; multivariable log-binomial regression modeling was used to evaluate factors associated with antimicrobial use. Of 12 299 patients in 199 hospitals, 6084 (49.5%; 95% CI, 48.6–50.4%) received antimicrobials. Among 148 hospitals in both surveys, overall antimicrobial use prevalence was similar in 2011 and 2015, although the percentage of neonatal critical care patients on antimicrobials was lower in 2015 (22.8% vs 32.0% [2011]; P = .006). Fluoroquinolone use was lower in 2015 (10.1% of patients vs 11.9% [2011]; P < .001). Third- or fourth-generation cephalosporin use was higher (12.2% vs 10.7% [2011]; P = .002), as was carbapenem use (3.7% vs 2.7% [2011]; P < .001). Overall hospital antimicrobial use prevalence was not different in 2011 and 2015; however, differences observed in selected patient or antimicrobial groups may provide evidence of stewardship impact.

12 April 2023 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
LKLarry K. Kociolek
Larry K. Kociolek
DGDale N. Gerding
Dale N. Gerding
RCRuth M Carrico
Ruth M Carrico
PCPhilip C. Carling
Philip C. Carling
CDCurtis J. Donskey
Curtis J. Donskey
EDErik R. Dubberke
Erik R. Dubberke

5 April 2017 in Current Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
GDGhinwa Dumyati
Ghinwa Dumyati
NSNimalie D. Stone
Nimalie D. Stone
DNDavid A. Nace
David A. Nace
CCChristopher J. Crnich
Christopher J. Crnich
RJRobin L. P. Jump
Robin L. P. Jump
Purpose of Review Nursing home residents are at high risk for colonization and infection with bacterial pathogens that are multidrug-resistant organisms (MDROs). We discuss challenges and potential solutions to support implementing effective infection prevention and control practices in nursing homes. Recent Findings Challenges include a paucity of evidence that addresses MDRO transmission during the care of nursing home residents, limited staff resources in nursing homes, insufficient infection prevention education in nursing homes, and perceptions by nursing home staff that isolation and contact precautions negatively influence the well being of their residents. Summary A small number of studies provide evidence that specifically address these challenges. Their outcomes support a paradigm shift that moves infection prevention and control practices away from a pathogen-specific approach and toward one that focuses on resident risk factors.

1 February 2012 in Emerging Infectious Diseases
Verified
Journal Article
Open access
GDGhinwa Dumyati
Ghinwa Dumyati
VSVanessa Stevens
Vanessa Stevens
GHGeorge E. Hannett
George E. Hannett
ATAngela D. Thompson
Angela D. Thompson
CLCherie Long
Cherie Long
BLBrandi Limbago
Brandi Limbago
We conducted active sentinel surveillance in Monroe County, New York, USA, to compare incidence of community-associated Clostridium difficile infections (CA-CDIs) with that of health care–associated infections (HA-CDIs) and identify exposure and strain type differences between CA and HA cases. Patients positive for C. difficile toxin and with no documented health care exposure in the previous 12 weeks were defined as possible CA case-patients. Patients with onset in a health care setting or recent health care exposure were defined as HA case-patients. Eighteen percent of CDIs were CA; 76% were in persons who reported antimicrobial drug use in the 12 weeks before CDI diagnosis. Strain type distribution was similar between CA and HA cases; North American pulsed-field 1 was the primary strain (31% CA, 42% HA; p = 0.34). CA-CDI is an emergent disease affecting patients recently exposed to antimicrobial drugs. Community strains are similar to those found in health care settings.

21 April 2023 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CGCheri Grigg
Cheri Grigg
KJKelly A Jackson
Kelly A Jackson
DBDevra Barter
Devra Barter
CCChristopher A Czaja
Christopher A Czaja
HJHelen Johnston
Helen Johnston
SMShelley S Magill
Shelley S Magill
Nontuberculous mycobacteria (NTM) cause pulmonary (PNTM) and extrapulmonary (ENTM) disease. Infections are difficult to diagnose and treat, and exposures occur in healthcare and community settings. In the United States, NTM epidemiology has been described largely through analyses of microbiology data from health departments, electronic health records, and administrative data. We describe findings from a multisite pilot of active, laboratory- and population-based NTM surveillance. The Centers for Disease Control and Prevention’s Emerging Infections Program conducted NTM surveillance at 4 sites (Colorado, 5 counties; Minnesota, 2 counties; New York, 2 counties; and Oregon, 3 counties [PNTM] and statewide [ENTM]) from 1 October 2019 through 31 March 2020. PNTM cases were defined using published microbiologic criteria. ENTM cases required NTM isolation from a nonpulmonary specimen, excluding stool and rectal swabs. Patient data were collected via medical record review. Overall, 299 NTM cases were reported (PNTM: 231, 77%); Mycobacterium avium complex was the most common species group. Annualized prevalence was 7.5/100 000 population (PNTM: 6.1/100 000; ENTM: 1.4/100 000). Most patients had signs or symptoms in the 14 days before positive specimen collection (ENTM: 62, 91.2%; PNTM: 201, 87.0%). Of PNTM cases, 145 (62.8%) were female and 168 (72.7%) had underlying chronic lung disease. Among ENTM cases, 29 (42.6%) were female, 21 (30.9%) did not have documented underlying conditions, and 26 (38.2%) had infection at the site of a medical device or procedure. Active, population-based NTM surveillance will provide data for monitoring the burden of disease and characterize affected populations to inform interventions.

14 February 2022 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
NDNadezhda Duffy
Nadezhda Duffy
MKMaria Karlsson
Maria Karlsson
HRHannah E. Reses
Hannah E. Reses
DCDavina Campbell
Davina Campbell
JDJonathan Daniels
Jonathan Daniels
ISIsaac See
Isaac See
Objective: The incidence of infections from extended-spectrum β-lactamase (ESBL)–producing Enterobacterales (ESBL-E) is increasing in the United States. We describe the epidemiology of ESBL-E at 5 Emerging Infections Program (EIP) sites.Methods: During October–December 2017, we piloted active laboratory- and population-based (New York, New Mexico, Tennessee) or sentinel (Colorado, Georgia) ESBL-E surveillance. An incident case was the first isolation from normally sterile body sites or urine of Escherichia coli or Klebsiella pneumoniae/oxytoca resistant to ≥1 extended-spectrum cephalosporin and nonresistant to all carbapenems tested at a clinical laboratory from a surveillance area resident in a 30-day period. Demographic and clinical data were obtained from medical records. The Centers for Disease Control and Prevention (CDC) performed reference antimicrobial susceptibility testing and whole-genome sequencing on a convenience sample of case isolates.Results: We identified 884 incident cases. The estimated annual incidence in sites conducting population-based surveillance was 199.7 per 100,000 population. Overall, 800 isolates (96%) were from urine, and 790 (89%) were E. coli. Also, 393 cases (47%) were community-associated. Among 136 isolates (15%) tested at the CDC, 122 (90%) met the surveillance definition phenotype; 114 (93%) of 122 were shown to be ESBL producers by clavulanate testing. In total, 111 (97%) of confirmed ESBL producers harbored a blaCTX-M gene. Among ESBL-producing E. coli isolates, 52 (54%) were ST131; 44% of these cases were community associated.Conclusions: The burden of ESBL-E was high across surveillance sites, with nearly half of cases acquired in the community. EIP has implemented ongoing ESBL-E surveillance to inform prevention efforts, particularly in the community and to watch for the emergence of new ESBL-E strains.